• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Cassava Sciences, Inc.

    Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Resolves SEC Investigation
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Names Rick Barry as Chief Executive Officer
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Expansion of Open-Label Extension Trials
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers MDXG SAVA SRPT
    Cassava Sciences Issues Statement on Former Science Advisor
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Redemption Date Announced for Warrants
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Appoints Three New Members to its Board of Directors
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Tickers SAVA
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.